Clinical Trial Update: Dose Range-finding Study of ASP1585 in Chronic Kidney Disease Patients on Hemodialysis With Hyperphosphatemia [Phase 2]

View source ↗

Summary

Phase 2 dose-range finding trial of ASP1585 in chronic kidney disease patients on hemodialysis with hyperphosphatemia has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• End-stage Renal Disease

Drugs mentioned

• ASP1585 (ASP1585)

Snippet

Sponsor: Astellas Pharma Inc | Conditions: Chronic Kidney Disease Patients on Hemodialysis With Hyperphosphatemia | Phase 2 | Status: COMPLETED